Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669461 · ClinicalTrials.gov registry record · NA
Lubiprostone as a Treatment for Constipation in Parkinson's Disease
A NA study, sponsored by University of Arkansas.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00669461 is a NA study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 1 participants.
The verdict
NCT00669461, a NA study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to accelerate colonic transit time in healthy volunteers in addition to activating the chloride channels in the intestinal cells, it has the potential to improve constipation in patients with PD with no subsequent adverse events on the control of the neurological manifestation of PD. So we hypothesize the following: 1. Lubiprostone will improve ratings on the Bristol stool form scale (BSFS) in patients with PD induced constipation compared to baseline.(primary) 2. Lubiprostone will increase the number of spontaneous bowel movements (SBM) per week, compared to baseline. (secondary) 3. Lubiprostone will improve health related quality of life in subjects with PD induced constipation. ( secondary)
Interventions
- DRUG Lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669461
The ClinicalTrials.gov registry entry for NCT00669461 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lubiprostone is the first listed.
NCT00669461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669461 about?
NCT00669461 is a clinical study titled "Lubiprostone as a Treatment for Constipation in Parkinson's Disease". Delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to accelerate colonic transit time in healthy volunteers in addition to activating the chloride channels in the intestinal c...
What is the current status of trial NCT00669461?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00669461?
The interventions under investigation include: Lubiprostone (DRUG).
Who is sponsoring clinical trial NCT00669461?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.